Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant988 active trials8 approved drugs63 evidence items
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,217 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04146298 | Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 30 | Changhai HospitalOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06730009 | Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients | recruiting | Phase 1 / Phase 2 | 42 | Medigen Biotechnology CorporationINDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07284277 | TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC) | recruiting | Phase 1 / Phase 2 | 30 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05040360 | Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | recruiting | Phase 2 | 141 | SWOG Cancer Research NetworkNETWORK | 3 | Dec 15, 2025 | clinicaltrials |
| NCT03556228 | VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | recruiting | Phase 1 / Phase 2 | 242 | VM Oncology, LLCINDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06584227 | Adebrelimab and Chidamide for Pancreatic Cancer(ACPC) | recruiting | Phase 2 | 45 | Liu XiufengOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07269626 | PULSAR in Systemic Therapy for Pancreatic Cancer | recruiting | Phase 2 | 47 | Samsung Medical CenterOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT04570943 | Sequential Treatment With GEMBRAX and Then FOLFIRINOX Followed by Stereotactic MRI-guided Radiotherapy in Patients With Locally Advanced Pancreatic Cancer(GABRINOX-ART) | recruiting | Phase 2 | 103 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT06782932 | Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT05786716 | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06333314 | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE) | recruiting | Phase 2 | 120 | UNICANCEROTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07230509 | Pancreatic Parenchymal Injection of N-butyl-2-cyanoacrylate(NBCA) | recruiting | Phase 2 | 90 | Minia UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07257523 | Carbon Ion Radiotherapy in Frail Patients With Pancreatic Cancer | recruiting | Phase 2 | 33 | Yonsei UniversityOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259590 | A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation | recruiting | Phase 1 / Phase 2 | 126 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03492671 | Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer | recruiting | Phase 2 | 30 | Loma Linda UniversityOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05116072 | Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula(TPIAT-01) | recruiting | Phase 1 / Phase 2 | 36 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06770439 | IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer | recruiting | Phase 2 | 64 | Zhejiang UniversityOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06767813 | Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | recruiting | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06831136 | Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma(PANCARDINAL-2) | recruiting | Phase 2 | 24 | The University of Texas Health Science Center, HoustonOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT06758544 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Resectable Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 18 | Guangdong Provincial People's HospitalOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06298916 | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer(PHANTOM) | recruiting | Phase 1 / Phase 2 | 26 | Lantheus Medical ImagingINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06095141 | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency(PTCA199-6) | recruiting | Phase 2 / Phase 3 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06149689 | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer(PTCA199-7) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06249321 | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy(PTCA199-10) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07101679 | A Study of GnP RegimenCombined With Serplulimab and Stereotactic Body Radiation Therapy as First-line Treatment for Locally Advanced Pancreatic Cancer | recruiting | Phase 2 | 23 | West China HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07098598 | Pancreatic Cancer Diagnosis With FAPI-PET Imaging | recruiting | Phase 2 / Phase 3 | 100 | Turku University HospitalOTHER_GOV | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02843945 | Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | recruiting | Phase 1 / Phase 2 | 80 | CivaTech OncologyINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05944237 | HTL0039732 in Participants With Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 150 | Cancer Research UKOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | recruiting | Phase 2 | 37 | Susan E. BatesOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06944106 | A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04084496 | mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients | recruiting | Phase 2 | 80 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06538857 | CEB-01 in Locally Resectable Pancreatic Cancer | recruiting | Phase 2 | 39 | CEBIOTEXINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06532617 | Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06962267 | A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type) | recruiting | Phase 2 | 50 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04503265 | A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 122 | AtlasMedx, IncorporatedINDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT05827796 | IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 70 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06914674 | Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas(SPTP) | recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT05776524 | Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer | recruiting | Phase 2 | 46 | THERABIONIC INC.OTHER | 1 | Mar 25, 2025 | clinicaltrials |
| NCT06757244 | DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer(DOVIPA) | recruiting | Phase 2 | 35 | Hopital FochOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03579836 | Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | recruiting | Phase 1 / Phase 2 | 75 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06782412 | Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types(FAPIDO) | recruiting | Phase 2 / Phase 3 | 109 | KU LeuvenOTHER | 1 | Feb 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 24, 2025source: clinicaltrials